Planet B.io and ASR Dutch Science Park Fund are very happy to announce that two new companies have joined the Planet B.io community on the Biotech Campus Delft from April 1st on.
GenScript Biotech Corporation
Founded in 2002 in New Jersey, USA, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to Make People and Nature Healthier Through Biotechnology, and its role as a trusted global leader, GenScript has a team of over 5,500 employees and has served more than 200,000 customers across over 100 countries and regions. By moving into the ground floor of the Van Iterson House, GenScript is taking a significant step in establishing an mRNA lab in Europe.
Lesaffre
Lesaffre is a global leader in fermentation and biotechnology. Founded in 1853 and headquartered in Marcq-en-Baroeul, France, the company opened its first Dutch office at the Biotech Campus Delft on October 1, 2024, after acquiring dsm-firmenich’s yeast extract business. This strategic move enabled Biospringer, Lesaffre’s business unit focusing on yeast fermentation, to integrate with dsm-firmenich’s yeast business. The integration involved transfer of innovative processing technologies and products, as well as 46 dsm-firmenich employees working on yeast extracts. From April 1st on, Lesaffre has moved into the 2nd floor of the Beijerinck Center.
Planet B.io and ASR Dutch Science Park Fund are excited to see these corporates join the growing ecosystem at the Biotech Campus Delft.
Cindy Gerhardt, Managing Director of Planet B.io, shares: "We are happy to welcome GenScript and Lesaffre to our community. As established global players in biotechnology and fermentation, they bring valuable expertise in synthetic biology, bioprocessing, and industrial applications. We are sure they will add tremendous value to our ecosystem by sharing their knowledge, collaborating with fellow innovators, and strengthening the biotech landscape here at our campus and in the Netherlands.”
Martin Kraaij, fund director ASR Dutch Science Park Fund: “By investing in office and laboratory buildings on the Biotech Campus Delft, we can offer companies such as GenScript and Lesaffre a place where they can work on innovations and products that contribute to the world of tomorrow. In this way, the ASR Dutch Science Park Fund has a positive impact on the ecosystems of science parks and supports the Dutch knowledge economy."